Special Issue

Wnt Signaling in Cancer: New Advances

Message from the Guest Editor

Wnt signaling is one of the most fundamental signaling pathways in Metazoa. Depending on different combinations of ligands and receptors, the Wnt signaling transduction cascade can activate different pathways, which are categorized into two main groups: signaling pathway and the non-canonical (or \(\mathbb{\text{\mathbb{G}}}\)-cateninindependent) pathways. These pathways regulate key aspects of embryonic development by controlling differentiation, proliferation, and migration. Numerous malignant tumors have been described as modulated by Wnt signaling, such as Colorectal cancer, Breast cancer, Skin cancer, Pancreatic cancer, Liver cancer, and Leukemia, among others. However, to date, there are no FDA-approved specific Wnt-targeting therapies. In this Special Issue, we will focus on novel findings in the regulation of neoplasia through Wnt signaling, reviews detailing the relevance of this pathway to tumorigenesis, and the potential of targeting Wnt signaling as a therapeutic strategy to treat cancer. I look forward to your contribution.

Guest Editor

Dr. Danilo Predes

Department of Neurology, F. M Kirby Neurobiology Center, Boston Children's Hospital, Boston, MA, USA

Deadline for manuscript submissions

closed (20 December 2024)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/205634

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

